Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04639843
Title Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

mature T-cell and NK-cell lymphoma

anaplastic large cell lymphoma

peripheral T-cell lymphoma

breast implant-associated anaplastic large cell lymphoma

adult T-cell leukemia/lymphoma

angioimmunoblastic T-cell lymphoma



Azacitidine + Doxorubicin + Duvelisib + Romidepsin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.